Q2 2023 · 13F-HR
NEA Management Company, LLCholdings as filed
Filed 2023-08-11 · accession 0001012975-23-000333
$1.31B
Reported value
44
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 22266M104 | COUR | COURSERA INC | $167.5M | 12.8% | 12,867,769 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $118.4M | 9.04% | 3,745,262 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $118.1M | 9.01% | 5,108,563 | Common | SOLE |
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $89.1M | 6.80% | 1,587,854 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $77.1M | 5.89% | 24,137,931 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $68.5M | 5.23% | 21,347,838 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $56.6M | 4.32% | 2,186,243 | Common | SOLE |
| 084656107 | — | BERKSHIRE GREY INC | $53.8M | 4.11% | 38,183,023 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $52.7M | 4.02% | 7,692,298 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $48.0M | 3.66% | 2,909,956 | Common | SOLE |
| 05156V102 | AUPH | AURINIA PHARMACEUTICALS INC | $38.4M | 2.93% | 3,969,834 | Common | SOLE |
| 126638105 | CVRX | CVRX INC | $36.6M | 2.79% | 2,370,542 | Common | SOLE |
| 10920V404 | — | BRIGHT HEALTH GROUP INC | $33.3M | 2.54% | 2,726,917 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $29.1M | 2.22% | 14,986,793 | Common | SOLE |
| 75974E103 | — | RENEO PHARMACEUTICALS INC | $28.3M | 2.16% | 4,785,494 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $27.2M | 2.07% | 11,370,376 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $26.8M | 2.05% | 6,147,260 | Common | SOLE |
| 25058X105 | — | DESKTOP METAL INC | $25.5M | 1.95% | 14,407,594 | Common | SOLE |
| 65345N106 | NN | NEXTNAV INC | $24.1M | 1.84% | 8,189,156 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS INC | $22.5M | 1.71% | 4,448,757 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $18.3M | 1.40% | 1,276,595 | Common | SOLE |
| 98955G103 | — | ZEROFOX HLDGS INC | $18.1M | 1.38% | 18,068,513 | Common | SOLE |
| 00653A107 | ADAPY | ADAPTIMMUNE THERAPEUTICS PLC | $15.8M | 1.21% | 17,079,778 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $13.6M | 1.04% | 2,437,689 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $12.7M | 0.97% | 1,250,001 | Common | SOLE |
| 15870P307 | CSBR | CHAMPIONS ONCOLOGY INC | $10.9M | 0.83% | 1,713,720 | Common | SOLE |
| 90114C107 | TUYA | TUYA INC | $9.3M | 0.71% | 4,934,640 | Common | SOLE |
| 60343F106 | — | MINERVA SURGICAL INC | $8.8M | 0.67% | 34,437,052 | Common | SOLE |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $8.3M | 0.63% | 4,764,440 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $7.8M | 0.60% | 3,568,781 | Common | SOLE |
| 12430A102 | — | BUZZFEED INC | $7.7M | 0.59% | 15,333,892 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $6.2M | 0.48% | 481,677 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $5.9M | 0.45% | 1,462,586 | Common | SOLE |
| 528872302 | LXRX | LEXICON PHARMACEUTICALS INC | $5.5M | 0.42% | 2,382,286 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $4.2M | 0.32% | 3,467,406 | Common | SOLE |
| 57055L206 | MRKR | MARKER THERAPEUTICS INC | $3.3M | 0.25% | 1,071,428 | Common | SOLE |
| 75915K200 | — | REGULUS THERAPEUTICS INC | $2.9M | 0.22% | 1,945,579 | Common | SOLE |
| 81726A100 | — | SENTI BIOSCIENCES INC | $2.8M | 0.21% | 4,426,151 | Common | SOLE |
| N01045108 | — | AFFIMED NV | $2.6M | 0.20% | 4,426,488 | Common | SOLE |
| 87166L100 | — | SYNLOGIC INC | $1.8M | 0.14% | 4,228,940 | Common | SOLE |
| 270087208 | — | EARGO INC | $1.0M | 0.08% | 207,886 | Common | SOLE |
| 00654J107 | — | ADDEX THERAPEUTICS LTD | $632,885 | 0.05% | 180,000 | Common | SOLE |
| 96328L205 | 2CH | WHEELS UP EXPERIENCE INC | $124,167 | 0.01% | 106,126 | Common | SOLE |
| 00972G108 | — | AKARI THERAPEUTICS PLC | $76,868 | 0.01% | 452,167 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.